Jamaica's Ministry Of Health Completes Registration Of Entire United Cannabis Corporation Prana Line Patent-Protected Line
February 15 2018 - 8:40AM
InvestorsHub NewsWire
Patent-Protected Line Includes Active and Non-Active
Capsules, Sublinguals, Transdermals, Topicals, Vape Formulations
And Infused Water
Denver, CO --
February 15,
2018 -- InvestorsHub NewsWire
-- United Cannabis Corporation
(OTCBB:
CNAB) (the "Company" or "United Cannabis") today announced that
Jamaica's Ministry of Health has approved its entire patent-protected
Prana
collection
for use by
registered medicinal cannabis
patients.
UNITED CANNABIS
CORPORATION
JAMAICAN MINISTRY PRODUCT
REGISTRATION
|
|
Non-Active Capsules
10,20,50 mg
|
Active Capsules
10,20,50 mg
|
Sublingual
400 mg
|
Transdermal
|
Topical
|
Vape Formulation
|
Water
|
P1
|
X
|
X
|
X
|
X
|
X
|
X
|
|
P2
|
X
|
X
|
X
|
|
|
X
|
|
P3
|
X
|
X
|
X
|
X
|
|
X
|
|
P4
|
|
X
|
X
|
X
|
|
X
|
|
P5
|
|
X
|
X
|
X
|
X
|
X
|
X
|
|
|
|
|
|
|
|
|
The Prana Collection is the
foundation of the Company's cannabis-centric formulations, which
patients have found effective in helping manage the symptoms of arthritis,
neuropathy, acute pain, joint aches, muscle tension, muscle spasms,
muscle recovery, migraines, and various skin conditions.
Earnest Blackmon, Chief
Executive Officer of United Cannabis, commented on the
announcement, "The Jamaican market continues to be favorable, on
both a regulatory and operational basis, enabling us to diversify
out of the United States. Of course, we remain confident that the
US market will continue to move toward legalization of medical
cannabis, but with our complete line now registered with the
Ministry of Health, Jamaica can also serve as a gateway to other
open markets. We, along with our partners, are already talking with
customers in Canada, Australia, New Zealand, The Philippines and
Nigeria."
About Cannabinoid Research
& Development Limited
Cannabinoid Research &
Development (CRD), a subsidiary of
United Cannabis, is
a Jamaican based corporation pursuing local licensing to advance
the use of medical cannabis therapies through biomedical research
and development for the nutraceutical industry.
CRD
focuses on genetic
restoration, cannabinoid isolation techniques, scientific research,
educational programs, and promotes domestic job opportunities. John
Sayers, along with Kenyama
Brown, local
Jamaican directors and executives
of CRD,
coupled with
Jamaican partners specializing in agricultural science and plant
based medicine, will help United Cannabis
implement Sayer's 40 years of agricultural
methodologies into localized educational curriculums, job training
programs, and help with integration of localized
products.
About United Cannabis
Corporation
United Cannabis
Corporation is a biotechnology company dedicated to the development
of phyto-therapeutic based
products supported by patented technologies for the pharmaceutical,
medical, and industrial markets. The Company
has long advocated the application of cannabinoids
for medical applications and is building a platform for designing
targeted therapies to increase the quality of life for patients
around the world. The Company's products are patent
protected
first in class
medicines with applications to a global market. United Cannabis
trades on the OTCQB under the symbol CNAB.
For further
information, please visit www.unitedcannabis.us.
Contact: Staff@UnitedCannabis.us
Phone: 303-386-7321
Certain
statements in this news release may contain forward-looking
information within the meaning of Rule 175 under the Securities Act
of 1933, are subject to Rule 3b-6 under the Securities Exchange Act
of 1934, and are subject to the safe harbors created by those
rules. All statements, other than statements of fact, included in
this release, including, without limitation, statements regarding
potential future plans and objectives of the company, are
forward-looking statements that involve risks and uncertainties.
There can be no assurance that such statements will prove to be
accurate and other results and further events could differ
materially from those anticipated in such statements. Future events
and actual results could differ materially from those set forth in,
contemplated by, or underlying the forward-looking
statements.